Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
Identifieur interne : 000227 ( Main/Corpus ); précédent : 000226; suivant : 000228Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
Auteurs : Guillaume Hache ; Jean Marc Rolain ; Philippe Gautret ; Jean-Claude Deharo ; Philippe Brouqui ; Didier Raoult ; Stéphane HonoréSource :
- Microbial drug resistance (Larchmont, N.Y.) [ 1931-8448 ] ; 2021.
English descriptors
- KwdEn :
- Anti-Bacterial Agents (administration & dosage), Anti-Bacterial Agents (adverse effects), Anti-Bacterial Agents (pharmacology), Anti-Bacterial Agents (therapeutic use), Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Azithromycin (administration & dosage), Azithromycin (adverse effects), Azithromycin (pharmacology), Azithromycin (therapeutic use), COVID-19 (drug therapy), Dose-Response Relationship, Drug (MeSH), Drug Interactions (MeSH), Drug Therapy, Combination (MeSH), Humans (MeSH), Hydroxychloroquine (administration & dosage), Hydroxychloroquine (adverse effects), Hydroxychloroquine (pharmacology), Hydroxychloroquine (therapeutic use), SARS-CoV-2 (MeSH).
- MESH :
- chemical , administration & dosage : Anti-Bacterial Agents, Antiviral Agents, Azithromycin, Hydroxychloroquine.
- chemical , adverse effects : Anti-Bacterial Agents, Antiviral Agents, Azithromycin, Hydroxychloroquine.
- chemical , pharmacology : Anti-Bacterial Agents, Antiviral Agents, Azithromycin, Hydroxychloroquine.
- chemical , therapeutic use : Anti-Bacterial Agents, Antiviral Agents, Azithromycin, Hydroxychloroquine.
- drug therapy : COVID-19.
- Dose-Response Relationship, Drug, Drug Interactions, Drug Therapy, Combination, Humans, SARS-CoV-2.
Abstract
The coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2, has recently emerged worldwide. In this context, there is an urgent need to identify safe and effective therapeutic strategies for treatment of such highly contagious disease. We recently reported promising results of combining hydroxychloroquine and azithromycin as an early treatment option. Although ongoing clinical trials are challenging the efficacy of this combination, many clinicians claim the authorization to or have already begun to use it to treat COVID-19 patients worldwide. The aim of this article is to share pharmacology considerations contributing to the rationale of this combination, and to provide safety information to prevent toxicity and drug-drug interactions, based on available evidence.
DOI: 10.1089/mdr.2020.0232
PubMed: 33729874
PubMed Central: PMC7987362
Links to Exploration step
pubmed:33729874Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.</title><author><name sortKey="Hache, Guillaume" sort="Hache, Guillaume" uniqKey="Hache G" first="Guillaume" last="Hache">Guillaume Hache</name><affiliation><nlm:affiliation>Service de Pharmacie, Hôpital de la Timone, APHM, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rolain, Jean Marc" sort="Rolain, Jean Marc" uniqKey="Rolain J" first="Jean Marc" last="Rolain">Jean Marc Rolain</name><affiliation><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gautret, Philippe" sort="Gautret, Philippe" uniqKey="Gautret P" first="Philippe" last="Gautret">Philippe Gautret</name><affiliation><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Deharo, Jean Claude" sort="Deharo, Jean Claude" uniqKey="Deharo J" first="Jean-Claude" last="Deharo">Jean-Claude Deharo</name><affiliation><nlm:affiliation>Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Service de Cardiologie, Hôpital de la Timone, APHM, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Brouqui, Philippe" sort="Brouqui, Philippe" uniqKey="Brouqui P" first="Philippe" last="Brouqui">Philippe Brouqui</name><affiliation><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Raoult, Didier" sort="Raoult, Didier" uniqKey="Raoult D" first="Didier" last="Raoult">Didier Raoult</name><affiliation><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Honore, Stephane" sort="Honore, Stephane" uniqKey="Honore S" first="Stéphane" last="Honoré">Stéphane Honoré</name><affiliation><nlm:affiliation>Service de Pharmacie, Hôpital de la Timone, APHM, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Univ, Laboratoire de Pharmacie Clinique, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33729874</idno><idno type="pmid">33729874</idno><idno type="doi">10.1089/mdr.2020.0232</idno><idno type="pmc">PMC7987362</idno><idno type="wicri:Area/Main/Corpus">000227</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000227</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.</title><author><name sortKey="Hache, Guillaume" sort="Hache, Guillaume" uniqKey="Hache G" first="Guillaume" last="Hache">Guillaume Hache</name><affiliation><nlm:affiliation>Service de Pharmacie, Hôpital de la Timone, APHM, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rolain, Jean Marc" sort="Rolain, Jean Marc" uniqKey="Rolain J" first="Jean Marc" last="Rolain">Jean Marc Rolain</name><affiliation><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Gautret, Philippe" sort="Gautret, Philippe" uniqKey="Gautret P" first="Philippe" last="Gautret">Philippe Gautret</name><affiliation><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Deharo, Jean Claude" sort="Deharo, Jean Claude" uniqKey="Deharo J" first="Jean-Claude" last="Deharo">Jean-Claude Deharo</name><affiliation><nlm:affiliation>Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Service de Cardiologie, Hôpital de la Timone, APHM, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Brouqui, Philippe" sort="Brouqui, Philippe" uniqKey="Brouqui P" first="Philippe" last="Brouqui">Philippe Brouqui</name><affiliation><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Raoult, Didier" sort="Raoult, Didier" uniqKey="Raoult D" first="Didier" last="Raoult">Didier Raoult</name><affiliation><nlm:affiliation>IHU-Méditerranée Infection, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Honore, Stephane" sort="Honore, Stephane" uniqKey="Honore S" first="Stéphane" last="Honoré">Stéphane Honoré</name><affiliation><nlm:affiliation>Service de Pharmacie, Hôpital de la Timone, APHM, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix Marseille Univ, Laboratoire de Pharmacie Clinique, Marseille, France.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Microbial drug resistance (Larchmont, N.Y.)</title><idno type="eISSN">1931-8448</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Bacterial Agents (administration & dosage)</term><term>Anti-Bacterial Agents (adverse effects)</term><term>Anti-Bacterial Agents (pharmacology)</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>Azithromycin (administration & dosage)</term><term>Azithromycin (adverse effects)</term><term>Azithromycin (pharmacology)</term><term>Azithromycin (therapeutic use)</term><term>COVID-19 (drug therapy)</term><term>Dose-Response Relationship, Drug (MeSH)</term><term>Drug Interactions (MeSH)</term><term>Drug Therapy, Combination (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (administration & dosage)</term><term>Hydroxychloroquine (adverse effects)</term><term>Hydroxychloroquine (pharmacology)</term><term>Hydroxychloroquine (therapeutic use)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Antiviral Agents</term><term>Azithromycin</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Antiviral Agents</term><term>Azithromycin</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Antiviral Agents</term><term>Azithromycin</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Antiviral Agents</term><term>Azithromycin</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Drug</term><term>Drug Interactions</term><term>Drug Therapy, Combination</term><term>Humans</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2, has recently emerged worldwide. In this context, there is an urgent need to identify safe and effective therapeutic strategies for treatment of such highly contagious disease. We recently reported promising results of combining hydroxychloroquine and azithromycin as an early treatment option. Although ongoing clinical trials are challenging the efficacy of this combination, many clinicians claim the authorization to or have already begun to use it to treat COVID-19 patients worldwide. The aim of this article is to share pharmacology considerations contributing to the rationale of this combination, and to provide safety information to prevent toxicity and drug-drug interactions, based on available evidence.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33729874</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1931-8448</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Microbial drug resistance (Larchmont, N.Y.)</Title><ISOAbbreviation>Microb Drug Resist</ISOAbbreviation></Journal><ArticleTitle>Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.</ArticleTitle><Pagination><MedlinePgn>281-290</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/mdr.2020.0232</ELocationID><Abstract><AbstractText>The coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2, has recently emerged worldwide. In this context, there is an urgent need to identify safe and effective therapeutic strategies for treatment of such highly contagious disease. We recently reported promising results of combining hydroxychloroquine and azithromycin as an early treatment option. Although ongoing clinical trials are challenging the efficacy of this combination, many clinicians claim the authorization to or have already begun to use it to treat COVID-19 patients worldwide. The aim of this article is to share pharmacology considerations contributing to the rationale of this combination, and to provide safety information to prevent toxicity and drug-drug interactions, based on available evidence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hache</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Service de Pharmacie, Hôpital de la Timone, APHM, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rolain</LastName><ForeName>Jean Marc</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>IHU-Méditerranée Infection, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gautret</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>IHU-Méditerranée Infection, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deharo</LastName><ForeName>Jean-Claude</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service de Cardiologie, Hôpital de la Timone, APHM, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brouqui</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>IHU-Méditerranée Infection, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raoult</LastName><ForeName>Didier</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>IHU-Méditerranée Infection, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honoré</LastName><ForeName>Stéphane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de Pharmacie, Hôpital de la Timone, APHM, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aix Marseille Univ, Laboratoire de Pharmacie Clinique, Marseille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, Marseille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microb Drug Resist</MedlineTA><NlmUniqueID>9508567</NlmUniqueID><ISSNLinking>1076-6294</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">azithromycin</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>17</Day><Hour>17</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33729874</ArticleId><ArticleId IdType="doi">10.1089/mdr.2020.0232</ArticleId><ArticleId IdType="pmc">PMC7987362</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Intensive Care Med. 2013 Apr;39(4):693-702</Citation><ArticleIdList><ArticleId IdType="pubmed">23344833</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2004 Jan 19;484(1):41-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14729380</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2000 Dec;27(12):2927-31</Citation><ArticleIdList><ArticleId IdType="pubmed">11128688</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacotherapy. 2001 Nov;21(11):1436-43</Citation><ArticleIdList><ArticleId IdType="pubmed">11714218</ArticleId></ArticleIdList></Reference><Reference><Citation>New Microbes New Infect. 2020 Jun 06;38:100709</Citation><ArticleIdList><ArticleId IdType="pubmed">33088574</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Pharm Fr. 2008 Nov-Dec;66(5-6):268-77</Citation><ArticleIdList><ArticleId IdType="pubmed">19061726</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2012 May 17;366(20):1881-90</Citation><ArticleIdList><ArticleId IdType="pubmed">22591294</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Saf. 2018 Oct;41(10):919-931</Citation><ArticleIdList><ArticleId IdType="pubmed">29858838</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathol Biol (Paris). 1995 Jun;43(6):505-11</Citation><ArticleIdList><ArticleId IdType="pubmed">8539072</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J. 2020 May 14;41(19):1798-1800</Citation><ArticleIdList><ArticleId IdType="pubmed">32186331</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart Rhythm. 2020 Sep;17(9):1425-1433</Citation><ArticleIdList><ArticleId IdType="pubmed">32407884</ArticleId></ArticleIdList></Reference><Reference><Citation>Postgrad Med J. 2006 Feb;82(964):140-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16461478</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 May;177:104762</Citation><ArticleIdList><ArticleId IdType="pubmed">32147496</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2012 Jul 25;308(4):353-61</Citation><ArticleIdList><ArticleId IdType="pubmed">22820788</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 2009 Aug;31(8):1737-46</Citation><ArticleIdList><ArticleId IdType="pubmed">19808132</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart Rhythm. 2020 Sep;17(9):1456-1462</Citation><ArticleIdList><ArticleId IdType="pubmed">32244059</ArticleId></ArticleIdList></Reference><Reference><Citation>Mediators Inflamm. 2012;2012:649570</Citation><ArticleIdList><ArticleId IdType="pubmed">22719178</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 2000 Apr 15;108(6):453-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10781777</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105938</Citation><ArticleIdList><ArticleId IdType="pubmed">32171740</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 1988 Sep;26(3):303-13</Citation><ArticleIdList><ArticleId IdType="pubmed">3179169</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2020 Aug;97:396-403</Citation><ArticleIdList><ArticleId IdType="pubmed">32623082</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2020 Nov;108(5):1090-1097</Citation><ArticleIdList><ArticleId IdType="pubmed">32588427</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101663</Citation><ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Toxicol. 2015 Jul;15(3):232-40</Citation><ArticleIdList><ArticleId IdType="pubmed">25367413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 1993 Nov 30;696:285-91</Citation><ArticleIdList><ArticleId IdType="pubmed">8109833</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 Jul - Aug;36:101791</Citation><ArticleIdList><ArticleId IdType="pubmed">32593867</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation><ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart Rhythm. 2020 Sep;17(9):1452-1455</Citation><ArticleIdList><ArticleId IdType="pubmed">32380291</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus. 2009 Feb;18(2):104-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19151110</ArticleId></ArticleIdList></Reference><Reference><Citation>Paediatr Respir Rev. 2018 Sep;28:68-79</Citation><ArticleIdList><ArticleId IdType="pubmed">29627169</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2019 Apr;81:184-190</Citation><ArticleIdList><ArticleId IdType="pubmed">30690213</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2007 Jul 11;298(2):187-93</Citation><ArticleIdList><ArticleId IdType="pubmed">17622600</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Immunol. 1995 Oct;102(1):144-51</Citation><ArticleIdList><ArticleId IdType="pubmed">7554381</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorax. 2015 Nov;70(11):1078-84</Citation><ArticleIdList><ArticleId IdType="pubmed">26135832</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1989 Apr;46(4):464-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2650665</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 2000 Jun;49(6):549-54</Citation><ArticleIdList><ArticleId IdType="pubmed">10848718</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Coll Cardiol. 2020 May 26;75(20):2623-2624</Citation><ArticleIdList><ArticleId IdType="pubmed">32283123</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Jun 23;323(24):2493-2502</Citation><ArticleIdList><ArticleId IdType="pubmed">32392282</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol Suppl. 1996 Mar;44:86-90</Citation><ArticleIdList><ArticleId IdType="pubmed">8833062</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Netw Open. 2020 Apr 24;3(4):e208857</Citation><ArticleIdList><ArticleId IdType="pubmed">32330277</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 2002 Oct;29(10):2077-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12375315</ArticleId></ArticleIdList></Reference><Reference><Citation>Transplant Proc. 1996 Aug;28(4):2316</Citation><ArticleIdList><ArticleId IdType="pubmed">8769234</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):215-221</Citation><ArticleIdList><ArticleId IdType="pubmed">32372695</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Trop Med Hyg. 2006 Mar;74(3):407-12</Citation><ArticleIdList><ArticleId IdType="pubmed">16525098</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Cardiol. 2020 Jun;36(6):948-951</Citation><ArticleIdList><ArticleId IdType="pubmed">32299753</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomed Res Int. 2018 Oct 14;2018:1574806</Citation><ArticleIdList><ArticleId IdType="pubmed">30406128</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2009 Apr;53(4):1468-75</Citation><ArticleIdList><ArticleId IdType="pubmed">19188392</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Drug Metab Toxicol. 2011 Sep;7(9):1153-67</Citation><ArticleIdList><ArticleId IdType="pubmed">21736423</ArticleId></ArticleIdList></Reference><Reference><Citation>Signal Transduct Target Ther. 2020 Mar 27;5(1):33</Citation><ArticleIdList><ArticleId IdType="pubmed">32296069</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupus. 2019 Jan;28(1):129-132</Citation><ArticleIdList><ArticleId IdType="pubmed">30428763</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Aug;56(2):106053</Citation><ArticleIdList><ArticleId IdType="pubmed">32534189</ArticleId></ArticleIdList></Reference><Reference><Citation>Med (N Y). 2020 Dec 18;1(1):114-127.e3</Citation><ArticleIdList><ArticleId IdType="pubmed">32838355</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2020 Aug;108(2):253-263</Citation><ArticleIdList><ArticleId IdType="pubmed">32285930</ArticleId></ArticleIdList></Reference><Reference><Citation>Microb Pathog. 2020 Aug;145:104228</Citation><ArticleIdList><ArticleId IdType="pubmed">32344177</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Drug Metab Pharmacokinet. 2020 Dec;45(6):715-723</Citation><ArticleIdList><ArticleId IdType="pubmed">32780273</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Intern Med. 2020 Aug;78:101-106</Citation><ArticleIdList><ArticleId IdType="pubmed">32586646</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ Arrhythm Electrophysiol. 2017 Apr;10(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">28408648</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med. 1988 Oct 14;85(4A):57-61</Citation><ArticleIdList><ArticleId IdType="pubmed">3052057</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Immunol. 2008 Nov;9(11):1288-96</Citation><ArticleIdList><ArticleId IdType="pubmed">18820682</ArticleId></ArticleIdList></Reference><Reference><Citation>Beijing Da Xue Xue Bao Yi Xue Ban. 2019 Dec 18;51(6):1178-1181</Citation><ArticleIdList><ArticleId IdType="pubmed">31848526</ArticleId></ArticleIdList></Reference><Reference><Citation>CPT Pharmacometrics Syst Pharmacol. 2020 Sep;9(9):509-514</Citation><ArticleIdList><ArticleId IdType="pubmed">32558354</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 18;382(25):2411-2418</Citation><ArticleIdList><ArticleId IdType="pubmed">32379955</ArticleId></ArticleIdList></Reference><Reference><Citation>Platelets. 2008 Nov;19(7):559-60</Citation><ArticleIdList><ArticleId IdType="pubmed">18979371</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Immunol. 2018 Mar 13;9:302</Citation><ArticleIdList><ArticleId IdType="pubmed">29593707</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheumatol. 2015 May;67(8):2176-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25989906</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2018 Jun;365(3):447-459</Citation><ArticleIdList><ArticleId IdType="pubmed">29438998</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Pharmacol. 2000 Oct;50(4):285-95</Citation><ArticleIdList><ArticleId IdType="pubmed">11012550</ArticleId></ArticleIdList></Reference><Reference><Citation>Wien Klin Wochenschr. 2002 Jun 14;114(10-11):396-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12708094</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2018 Apr 20;9:363</Citation><ArticleIdList><ArticleId IdType="pubmed">29731714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Drug Monit. 2003 Dec;25(6):671-81</Citation><ArticleIdList><ArticleId IdType="pubmed">14639053</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2004 Mar;48(3):809-14</Citation><ArticleIdList><ArticleId IdType="pubmed">14982769</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2002 Oct;303(1):218-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12235254</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Care Res (Hoboken). 2018 Mar;70(3):481-485</Citation><ArticleIdList><ArticleId IdType="pubmed">28556555</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1033-1034</Citation><ArticleIdList><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Cardiol. 2020 Sep 1;5(9):1036-1041</Citation><ArticleIdList><ArticleId IdType="pubmed">32936252</ArticleId></ArticleIdList></Reference><Reference><Citation>Eye (Lond). 2017 Jun;31(6):828-845</Citation><ArticleIdList><ArticleId IdType="pubmed">28282061</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthritis Rheum. 1999 Feb;42(2):357-65</Citation><ArticleIdList><ArticleId IdType="pubmed">10025931</ArticleId></ArticleIdList></Reference><Reference><Citation>Malar J. 2014 Nov 25;13:458</Citation><ArticleIdList><ArticleId IdType="pubmed">25425434</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleve Clin J Med. 2013 Sep;80(9):539-44</Citation><ArticleIdList><ArticleId IdType="pubmed">24001961</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 Jun;26(6):808-809</Citation><ArticleIdList><ArticleId IdType="pubmed">32488217</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Postepy Dermatol Alergol. 2018 Aug;35(4):429-430</Citation><ArticleIdList><ArticleId IdType="pubmed">30206460</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000227 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000227 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33729874
|texte= Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33729874" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |